Biogen (BIIB) vs peers

$251.93

Latest weekly close · Market cap $37.5B

BIIB's P/E is 44.8x, compared with 27.8x at the middle of 5 peers.

Peer group: Biotechnology. Updated Oct 23, 2026.

BIIB and Biotechnology, ranked by P/E
Stock	P/E	Own 5-year percentile
BIIBBiogen	44.8×	100
ABBVAbbVie	80.6×	76
VRTXVertex Pharmaceuticals	31.2×	86
AMGNAmgen	27.8×	78
REGNRegeneron Pharmaceuticals	20.2×	69
INCYIncyte	16.5×	13
GILDGilead Sciences	n/a	n/a, not ranked
MRNAModerna	n/a	n/a, not ranked
Peer median	27.8×

How to read this comparison

Up to eight covered companies in the same industry, largest market value first.

P/E divides the share price by earnings per share over the last twelve months. The peer median leaves out BIIB and stocks without a reading.

Each percentile compares a stock with its own weekly readings over the last five years, so 20 means its P/E is above 20% of its own past readings. It needs at least 26 weeks of history. It is not a rank against the other stocks in this table.

Different growth rates, margins and financial risks can explain different multiples. Stocks without positive earnings have no reading.

BIIB versus the peer median

+61%

BIIB: 44.8×
Peer median: 27.8×
Own 5-year median: 18.6×

BIIB P/E history Calculate BIIB's implied price